BiotechTube
Home/Galderma Group/Hervé Lilliu
HL

Hervé Lilliu

Chairman of the Board

Galderma Group

Therapeutic Areas

DermatologyAesthetic Medicine

Galderma Group Pipeline

DrugIndicationPhase
NemolizumabModerate-to-Severe Atopic Dermatitis (Adults/Adolescents)Approved/Filed
RelabotulinumtoxinA (QM1114)Aesthetic IndicationsPhase 3
Bimatoprost Sustained-ReleaseGlaucoma/Ocular HypertensionPhase 3
CD07805/47Inflammatory Dermatoses (e.g., Psoriasis)Phase 2
GM-502Androgenetic AlopeciaPhase 2
GM-503Acne VulgarisPhase 1

Leadership Team at Galderma Group

FØ
Flemming Ørnskov
Chief Executive Officer
AM
Andrew McConaghie
Chief Financial Officer
BS
Baldo Scassellati Sforzolini
Global Head of Research & Development
BF
Brett Feinstein
Chief Commercial Officer
View full Galderma Group profile